Dalfampridine 100 MG
Ended Awarded Last action
- Contract number
- VA77017J0435
- Awardee
-
Acorda Therapeutics, Inc. UEI R5D3FUPFFPK4
- Awarding agency
-
Veterans Integrated Service Network 15
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $485,835
Award facts
- Contract value 100% obligated
- $485,835.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Veterans Integrated Service Network 12 Veterans Health Administration, Department of Veterans Affairs
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Ardsley, NY 10502, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $6,975 | |
| Original award | $478,860 |
About this award
This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of January 26, 2017.
The contract is issued under Acorda Therapeutics' Federal Supply Schedule (FSS) contract with the VA, which is valued at over $16.3 million and covers the supply of drugs, pharmaceuticals, and hematology-related products through September 2024. Additionally, Acorda holds two Blanket Purchase Agreements (BPAs) with the VA National Acquisition Center, valued at $5.5 million and $7.5 million, specifically for the procurement of the company's neurological medications, Inbrija and Ampyra. These contract vehicles provide a streamlined process for VA medical facilities to order Acorda's products to support the agency's mission of providing quality healthcare to veterans.
There is no set-aside designation mentioned for this specific delivery order.
Quick answers
Who was awarded contract VA77017J0435?
VA77017J0435 was awarded to Acorda Therapeutics, Inc. by Veterans Integrated Service Network 15 (Veterans Health Administration) on January 17, 2017.
How much is contract VA77017J0435 worth?
The government has obligated $485,835 on VA77017J0435.
Which agency awarded contract VA77017J0435?
Veterans Integrated Service Network 15 (Veterans Health Administration) awarded VA77017J0435, with funding from Veterans Integrated Service Network 12 (Veterans Health Administration).
Is contract VA77017J0435 an order under another contract?
Yes. VA77017J0435 is a delivery order under V797P5233B, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract VA77017J0435 competed?
The extent of competition for VA77017J0435 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award